The Journal of Clinical Endocrinology & Metabolism2015Full TextOpen AccessHighly Cited

RM-493, a Melanocortin-4 Receptor (MC4R) Agonist, Increases Resting Energy Expenditure in Obese Individuals

Kong Y. Chen, Ranganath Muniyappa, Brent S. Abel et al.

174 citations2015Open Access — see publisher for license terms1 related compound

Research Article — Peer-Reviewed Source

Original research published by Chen et al. in The Journal of Clinical Endocrinology & Metabolism. Redistributed under Open Access — see publisher for license terms. MedTech Research Group provides these references for informational purposes. We do not conduct original research. All studies are the work of their respective authors and institutions.

Abstract

Short-term administration of the MC4R agonist RM-493 increases REE and shifts substrate oxidation to fat in obese individuals.

Full Text
01

Abstract

Context: Activation of the melanocortin-4 receptor (MC4R) with the synthetic agonist RM-493 decreases body weight and increases energy expenditure (EE) in nonhuman primates. The effects of MC4R agonists on EE in humans have not been examined to date. Objective, Design, and Setting: In a randomized, double-blind, placebo-controlled, crossover study, we examined the effects of the MC4R agonist RM-493 on resting energy expenditure (REE) in obese subjects in an inpatient setting. Study Participants and Methods: Twelve healthy adults (6 men and 6 women) with body mass index of 35.7 ± 2.9 kg/m 2 (mean ± SD) received RM-493 (1 mg/24 h) or placebo by continuous subcutaneous infusion over 72 hours, followed immediately by crossover to the alternate treatment. All subjects received a weight-maintenance diet (50% carbohydrate, 30% fat, and 20% protein) and performed 30 minutes of standardized exercise daily. Continuous EE was measured on the third treatment day in a room calorimeter, and REE in the fasting state was defined as the mean of 2 30-minute resting periods. Results: RM-493 increased REE vs placebo by 6.4% (95% confidence interval, 0.68–13.02%), on average by 111 kcal/24 h (95% confidence interval, 15–207 kcal, P = .03). Total daily EE trended higher, whereas the thermic effect of a test meal and exercise EE did not differ significantly. The 23-hour nonexercise respiratory quotient was lower during RM-493 treatment (0.833 ± 0.021 vs 0.848 ± 0.022, P = .02). No adverse effect on heart rate or blood pressure was observed. Conclusions: Short-term administration of the MC4R agonist RM-493 increases REE and shifts substrate oxidation to fat in obese individuals.

02

Context:

Activation of the melanocortin-4 receptor (MC4R) with the synthetic agonist RM-493 decreases body weight and increases energy expenditure (EE) in nonhuman primates. The effects of MC4R agonists on EE in humans have not been examined to date.

03

Objective, Design, and Setting:

In a randomized, double-blind, placebo-controlled, crossover study, we examined the effects of the MC4R agonist RM-493 on resting energy expenditure (REE) in obese subjects in an inpatient setting.

04

Study Participants and Methods:

Twelve healthy adults (6 men and 6 women) with body mass index of 35.7 ± 2.9 kg/m 2 (mean ± SD) received RM-493 (1 mg/24 h) or placebo by continuous subcutaneous infusion over 72 hours, followed immediately by crossover to the alternate treatment. All subjects received a weight-maintenance diet (50% carbohydrate, 30% fat, and 20% protein) and performed 30 minutes of standardized exercise daily. Continuous EE was measured on the third treatment day in a room calorimeter, and REE in the fasting state was defined as the mean of 2 30-minute resting periods.

05

Results:

RM-493 increased REE vs placebo by 6.4% (95% confidence interval, 0.68–13.02%), on average by 111 kcal/24 h (95% confidence interval, 15–207 kcal, P = .03). Total daily EE trended higher, whereas the thermic effect of a test meal and exercise EE did not differ significantly. The 23-hour nonexercise respiratory quotient was lower during RM-493 treatment (0.833 ± 0.021 vs 0.848 ± 0.022, P = .02). No adverse effect on heart rate or blood pressure was observed.

06

Conclusions:

Short-term administration of the MC4R agonist RM-493 increases REE and shifts substrate oxidation to fat in obese individuals.

Article Details
DOI10.1210/jc.2014-4024
PubMed ID25675384
PMC IDPMC4399297
JournalThe Journal of Clinical Endocrinology & Metabolism
Year2015
AuthorsKong Y. Chen, Ranganath Muniyappa, Brent S. Abel, Katherine Mullins, Pamela Staker, Robert J. Brychta, Xiongce Zhao, Michael Ring, Tricia Psota, Roger D. Cone, Brandon L. Panaro, Keith Gottesdiener, Lex H.T. Van der Ploeg, Marc L. Reitman, Monica C. Skarulis
LicenseOpen Access — see publisher for license terms
Citations174